Lymphokine-activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-γ injected around tumor-draining lymph nodes

This publication has 13 references indexed in Scilit:

• Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin-2 injected periiymphatically
  Cancer, 1988
• Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy
  Cancer and Metastasis Reviews, 1988
• In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta.
  The Journal of Experimental Medicine, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
  The Journal of Immunology, 1985
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.
  The Journal of Immunology, 1984
• In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomas
  International Journal of Cancer, 1983
• Allogeneic tumor rejection induced by the intravenous injection of Lyt-2+ cytolytic T lymphocyte clones.
  The Journal of Experimental Medicine, 1982
• Cell-Mediated Cytotoxicity, Allograft Rejection, and Tumor Immunity
  Published by Elsevier ,1974